Bristol Myers Squibb stock edges lower ahead of the open after a 0.17 percent dip
Published on 09/14/2026 at 08:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock closed at USD 63.64 on the NYSE on September 11, 2026, slipping 0.17 percent for the day. Compared with the broader S&P 500, which added 0.86 percent on the same date, the shares lagged the benchmark despite strong year-to-date gains.
September 11, 2026 in numbers
Bristol Myers Squibb Inc. (ISIN US0897961004, NYSE: BMY) ended the last completed session on September 11, 2026 at USD 63.64, down from a prior close of USD 63.75, for a 0.17 percent decline. According to data from Nasdaq real time pricing displayed by Yahoo Finance, the stock traded between a day low of USD 63.27 and a day high of USD 64.15, with volume of about 7.05 million shares in regular hours and a 52-week range of USD 42.52 to USD 68.64 on the NYSE. The same overview shows year-to-date performance of roughly 17.98 percent and a one-year gain of about 33.87 percent, indicating that the latest move came after a strong recovery phase.
Per the performance comparison table on Yahoo Finance, Bristol Myers Squibb’s trailing total return over one year of about 40.29 percent as of September 11, 2026 comfortably outpaced the S&P 500’s roughly 16.24 percent over the same period, underscoring how the stock has recently outperformed the broader market despite the modest setback in the latest session. In analyst coverage, HSBC maintained its hold rating on the shares while raising its price target to USD 65 on September 10, 2026, as reported by MarketWatch, adding a cautiously constructive note to sentiment around the stock.
Pipeline and events today
Into today’s session on September 14, 2026, investor attention remains on Bristol Myers Squibb’s development pipeline after new clinical data this week. As Simply Wall St reported on September 14, 2026, the company highlighted positive Phase 2 results for a blood cancer therapy, which could influence how investors view its medium-term growth prospects. The earnings calendar on Yahoo Finance lists Bristol Myers Squibb’s next scheduled earnings date as October 29, 2026, so today’s focus is likely to stay on clinical catalysts and broader healthcare sentiment rather than a company-specific results release.
